This site is currently implementing core features and is not ready for patient use yet.
This site is currently implementing core features and is not ready for patient use yet.
For informational purposes only — not medical advice
Get a free vaccination guide and nearby clinic recommendations — straight to your inbox.
How serious?
Risk of death
Yes
Vaccine available?
Time to symptoms
Countries affected
Active outbreaks
Primarily affects children under 5. Travelers with young children should ensure vaccination is complete. Oral rehydration salts are essential travel supplies for families.
Highly contagious viral gastroenteritis caused by rotavirus, primarily affecting infants and young children with severe watery diarrhea and vomiting.
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Diarrhea | 95% | Severe | Early |
| Vomiting | 90% | Moderate | Early |
| Abdominal cramps | 70% | Moderate | Early |
| Fever | 65% | Mild | Early |
| Irritability | 25% | Mild | Early |
| Loss of appetite | 30% | Mild | Early |
| Malaise | 40% | Mild | Early |
| Dehydration | 60% | Severe | Peak |
Rotavirus gastroenteritis is an acute diarrheal illness caused by rotaviruses, members of the family Reoviridae. Rotaviruses are non-enveloped, double-stranded RNA viruses classified into groups (A through J) based on the VP6 capsid protein, with group A responsible for the vast majority of human disease. Within group A, further classification by G-type (VP7 glycoprotein) and P-type (VP4 protease-sensitive protein) identifies circulating genotypes; globally dominant strains include G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and G12P[8].
Rotavirus is transmitted primarily through the fecal-oral route, either by direct person-to-person contact or through contaminated fomites, food, or water. The virus is extraordinarily environmentally stable, surviving for weeks on hard surfaces and for hours on hands. The infectious dose is extremely low: as few as 10–100 viral particles can cause infection, and an infected child may shed 10¹⁰–10¹¹ viral particles per gram of stool.
Before the introduction of rotavirus vaccines, rotavirus was the leading cause of severe dehydrating diarrhea in young children worldwide. Virtually all children experienced at least one rotavirus infection by age 5, regardless of socioeconomic status or geographic location. The WHO estimated that rotavirus caused approximately 527,000 deaths in children under 5 years in the year 2000, predominantly in low- and middle-income countries.
The development and global deployment of rotavirus vaccines represents one of the most impactful public health interventions of the 21st century, reducing rotavirus-associated mortality by more than 60% in countries with vaccine programs and preventing an estimated 50,000 deaths annually.
Rotavirus is the single most important cause of severe diarrhea in infants and young children globally. While the infection occurs universally across all populations, the consequences are starkly different between high-income and low-income settings: in high-income countries, rotavirus primarily causes healthcare visits and hospitalizations, whereas in low-income countries, it remains a major cause of childhood mortality due to dehydration.
The disease is most severe in children aged 6–24 months, a window of vulnerability between waning maternal antibody protection and the development of natural immunity through repeated exposures. By age 5, virtually every child has been infected, and subsequent infections tend to be progressively milder due to accumulating immunity. Adults can be infected (particularly the elderly and immunocompromised), but disease is typically mild.
Global burden (post-vaccine era): Despite vaccine availability, rotavirus continues to cause an estimated 128,500 deaths annually in children under 5 (2016 estimate), representing approximately 25–30% of all diarrheal deaths in this age group. An estimated 258 million diarrheal episodes in children under 5 are attributable to rotavirus annually, resulting in approximately 25 million clinic visits, 2 million hospitalizations, and the aforementioned mortality.
Two oral rotavirus vaccines are in widespread global use: RotaTeq (RV5, pentavalent human-bovine reassortant, 3-dose series) and Rotarix (RV1, monovalent attenuated human strain, 2-dose series). Both are administered in early infancy (starting at 6 weeks of age). The WHO recommends inclusion of rotavirus vaccine in all national immunization programs. As of 2024, 120+ countries have introduced rotavirus vaccines, with global coverage of approximately 50%.
Rotavirus gastroenteritis can progress from mild illness to life-threatening dehydration within hours, particularly in infants and young children. Caregivers should seek immediate emergency medical attention for:
Signs of severe dehydration (medical emergency):
No urine output for ≥6 hours (dry diapers in infants)
No tears when crying
Very dry mouth and tongue
Markedly sunken eyes or sunken fontanelle in infants
Skin that stays "tented" when pinched (loss of skin turgor)
Extreme lethargy, limp body, or unresponsiveness
Rapid, weak pulse or cold, mottled extremities (signs of shock)
Other emergency signs:
Persistent vomiting preventing any oral fluid intake for ≥4–6 hours
Bloody or bilious (green) vomiting
Bloody diarrhea (may indicate a different or co-existing pathogen)
High fever (>40°C) unresponsive to antipyretics
Seizures
Abdominal distension with absent bowel sounds (possible intussusception — a rare but recognized association with rotavirus)
Rapid breathing or difficulty breathing (may indicate severe metabolic acidosis from dehydration)
Seek prompt (non-emergency) medical evaluation for:
Moderate dehydration signs: decreased urine output, slightly sunken eyes, decreased activity level
Diarrhea lasting more than 7 days without improvement
Inability to maintain adequate oral rehydration despite small frequent sips
Any infant under 3 months with diarrhea and/or vomiting
Immunocompromised individuals with persistent symptoms
Early initiation of oral rehydration solution (ORS) at home is critical. Caregivers should begin ORS at the first sign of diarrhea, offering small frequent sips (5–10 mL every 1–2 minutes). This simple intervention prevents the majority of dehydration-related complications and deaths.
Most common signs and symptoms
Rotavirus gastroenteritis presents with a characteristic triad of watery diarrhea, vomiting, and fever, typically appearing abruptly after an incubation period of 1–3 days.
Vomiting is often the first symptom, preceding diarrhea by 12–24 hours. It occurs in approximately 80–90% of cases and is typically forceful and non-bilious. Vomiting is most intense during the first 1–2 days and generally subsides by day 3, but may persist longer in severe cases. The prominence of vomiting early in the illness course is an important clinical feature that distinguishes rotavirus from many bacterial diarrheal pathogens.
Diarrhea is watery, non-bloody, and often profuse. Stool output can reach 10–20 episodes per day in severe cases, with volumes of up to 100 mL/kg/day. The diarrhea typically lasts 3–8 days (mean 5 days). The absence of blood and mucus in stool is characteristic; the presence of blood should prompt consideration of alternative or co-existing bacterial pathogens. Stool may have a distinctive sour smell.
Fever occurs in 60–70% of children and is typically low to moderate grade (38–39°C), though temperatures up to 40°C may occur. Fever generally resolves within 2–3 days. Abdominal cramps and abdominal distension are common, with diffuse tenderness on palpation but no peritoneal signs.
The hallmark danger of rotavirus infection is dehydration, which develops rapidly in young children due to the combination of vomiting, diarrhea, fever, and reduced oral intake. Signs of dehydration include decreased urination, dry mucous membranes, sunken eyes, decreased skin turgor, sunken fontanelle (in infants), lethargy, and in severe cases, circulatory compromise. Severe dehydration (≥10% body weight loss) can progress to hypovolemic shock and death within hours if not corrected.
In adults and older children, rotavirus infection is generally mild or asymptomatic. Elderly individuals in institutional settings and immunocompromised patients may experience more prolonged and severe disease.
Knowing the symptoms is the first step to a quick response.
Rotavirus gastroenteritis follows a predictable clinical course with distinct phases.
Incubation period (1–3 days): Following ingestion of as few as 10–100 viral particles, rotavirus infects the mature enterocytes at the tips of small intestinal villi. Viral replication causes cellular lysis, villus blunting, and transient lactase deficiency. During the incubation period, viral replication proceeds without symptoms but viral shedding in stool begins 1–2 days before symptom onset.
Prodromal phase (12–24 hours): Many children experience a brief prodrome of low-grade fever, mild irritability, and decreased appetite before the onset of gastrointestinal symptoms. This phase may be absent in some cases, with abrupt onset of vomiting as the initial symptom.
Acute phase (days 1–3): Vomiting typically dominates the first 24–48 hours and may occur 5–10 times per day. Fever (38–39°C) peaks during this phase. Watery diarrhea begins within 12–24 hours of vomiting onset and quickly becomes the predominant symptom, with stools that are watery, voluminous, and free of blood or mucus. This phase carries the highest risk of dehydration due to the combination of fluid losses from vomiting, diarrhea, and fever with reduced oral intake.
Recovery phase (days 4–8): Vomiting subsides first (usually by day 2–3), followed by gradual reduction in diarrhea frequency and volume. Fever resolves. Appetite slowly returns. Stools transition from watery to loose to formed over several days. Temporary lactose intolerance (due to villous tip destruction and lactase deficiency) may persist for 2–4 weeks, causing bloating and loose stools with dairy consumption.
Convalescence (weeks 2–4): Complete mucosal recovery occurs over 2–4 weeks. Viral shedding gradually decreases but may persist for up to 2–3 weeks after symptom resolution (longer in immunocompromised patients). Nutritional catch-up occurs during this phase, and full restoration of absorptive capacity is expected in immunocompetent individuals.
How this disease is identified
Clinical diagnosis of rotavirus gastroenteritis is not reliably distinguishable from other causes of viral gastroenteritis on clinical grounds alone. Laboratory confirmation is achieved through detection of rotavirus in stool specimens.
Rapid antigen detection tests (immunochromatographic assays) are the most widely used diagnostic method in clinical settings. These lateral-flow tests detect group A rotavirus VP6 antigen in stool and provide results within 10–20 minutes. Sensitivity ranges from 70–90% and specificity from 85–99%, with best performance during the acute phase of illness when viral shedding is highest (first 3–5 days). Commercial examples include RIDA QUICK Rotavirus and SD Bioline Rota/Adeno.
Enzyme-linked immunosorbent assay (ELISA) for rotavirus VP6 antigen in stool is considered the reference standard for rotavirus detection in surveillance and research settings. Sensitivity exceeds 90% with specificity >95%. ELISA is more sensitive than rapid tests but requires laboratory equipment and takes 2–4 hours. It is the method recommended by WHO for rotavirus surveillance.
Reverse transcription PCR (RT-PCR) offers the highest sensitivity (95–100%) and enables genotyping (G-type and P-type determination), which is essential for vaccine effectiveness monitoring and epidemiological surveillance. RT-PCR can detect virus even when shedding levels are low, and is the preferred method for detecting vaccine-derived virus strains in post-vaccination shedding.
Electron microscopy was historically the first method used to identify rotavirus (1973, Ruth Bishop) and can visualize the characteristic 70 nm "wheel-like" viral particles. While no longer used for routine diagnosis, it remains a research tool for detecting novel rotavirus groups that may not be identified by group A-specific assays.
Specimen considerations: Stool specimens should be collected as early as possible in the illness (preferably within the first 48 hours) and can be stored at 4°C for up to 7 days or frozen at -20°C for prolonged storage. Viral shedding peaks on days 2–5 of illness and may persist for up to 2–3 weeks, though at declining levels.
Available treatment methods
There is no specific antiviral therapy for rotavirus infection. Treatment is entirely supportive, focused on prevention and correction of dehydration, which is the primary cause of morbidity and mortality.
Oral rehydration therapy (ORT) is the cornerstone of rotavirus treatment and one of the most important medical interventions in global child health:
Oral rehydration solution (ORS): The WHO low-osmolarity formulation (245 mOsm/L) containing sodium 75 mmol/L, glucose 75 mmol/L, potassium 20 mmol/L, and citrate 10 mmol/L is recommended. ORS should be administered in small, frequent volumes: 50–100 mL/kg over 4 hours for mild-moderate dehydration.
Continued feeding: Breastfeeding should continue throughout illness. Age-appropriate diet should be resumed as soon as tolerated — early refeeding reduces illness duration and improves nutritional recovery.
Avoid: Undiluted fruit juices, sugary drinks, and sports drinks (osmotic load worsens diarrhea). Avoid antidiarrheal medications (loperamide) in young children due to safety concerns.
Zinc supplementation is recommended by the WHO for all children with diarrhea in low- and middle-income countries: 20 mg/day for children ≥6 months and 10 mg/day for infants <6 months, for 10–14 days. Zinc reduces diarrhea duration by approximately 25% and stool output by 30%, and reduces the risk of subsequent diarrheal episodes for 2–3 months.
Intravenous fluid resuscitation is required for severe dehydration or when oral rehydration fails:
Severe dehydration/shock: Rapid IV bolus of 20 mL/kg isotonic saline (0.9% NaCl) or Ringer's lactate, repeated as needed, followed by calculated replacement of ongoing losses plus maintenance fluids.
Moderate dehydration with persistent vomiting: Nasogastric tube delivery of ORS at 20 mL/kg/hour is an effective alternative to IV fluids in settings with limited IV access.
Probiotics (particularly Lactobacillus rhamnosus GG and Saccharomyces boulardii) have demonstrated modest benefit in reducing diarrhea duration by 0.5–1 day, though evidence quality varies. Antiemetics (ondansetron) may reduce vomiting and improve oral rehydration success in emergency department settings.
Most cases are effectively treated with early diagnosis.
How to protect yourself
Rotavirus vaccination is the most effective prevention strategy and has transformed the epidemiology of severe childhood diarrhea worldwide. The WHO recommends that rotavirus vaccine be included in all national immunization programs.
Licensed vaccines:
RotaTeq (RV5): Pentavalent human-bovine reassortant vaccine containing G1, G2, G3, G4, and P[8] antigens. Administered as a 3-dose oral series at 2, 4, and 6 months of age. First dose should be given by 15 weeks of age, and the series completed by 32 weeks.
Rotarix (RV1): Monovalent attenuated human rotavirus vaccine (G1P[8] strain). Administered as a 2-dose oral series at 2 and 4 months of age. Despite containing a single strain, it provides significant cross-protection against non-G1 serotypes.
Additional vaccines: ROTAVAC (India, 116E strain), ROTASIIL (India, bovine-human reassortant), and other locally produced vaccines expand global access.
Vaccine efficacy in high-income countries is excellent: 85–98% against severe rotavirus gastroenteritis and 74–87% against any rotavirus gastroenteritis. In low-income countries, efficacy is lower (50–64% against severe disease in sub-Saharan Africa and South Asia), but the absolute number of cases prevented is greater due to higher disease incidence. The reasons for reduced efficacy in low-income settings include concurrent enteric infections, malnutrition, maternal antibody interference, and differences in gut microbiome.
Intussusception risk: A small increased risk of intussusception (approximately 1–6 additional cases per 100,000 vaccinated infants) has been documented in post-licensure surveillance. This risk is far outweighed by the benefits of vaccination, particularly in high-burden settings.
Hygiene and sanitation measures provide limited protection against rotavirus due to its extremely low infectious dose and environmental stability. Handwashing, safe water, and sanitation improvements — while critical for bacterial diarrheal diseases — have not demonstrated significant impact on rotavirus transmission. This underscores the irreplaceable role of vaccination in rotavirus prevention.
Breastfeeding provides moderate protection against severe rotavirus disease (estimated 50% reduction in hospitalization risk in exclusively breastfed infants), likely through secretory IgA and other innate immune factors in breast milk.
Preparation is the best protection.
Rotavirus is globally ubiquitous, and exposure risk exists in virtually all travel destinations. However, several travel-specific considerations are important for families traveling with young children and for travelers in general.
Pre-travel vaccination of infants: Parents planning international travel with infants should ensure their child has received the age-appropriate rotavirus vaccine doses before departure. The first dose should be administered by 15 weeks of age, and the series must be initiated and completed within the approved age window (by 8 months for Rotarix, 32 weeks for RotaTeq). Travel is not a reason to deviate from the recommended age-based schedule, as the vaccine is contraindicated outside the approved age window.
Risk in low-resource settings: While rotavirus exposure occurs worldwide, the consequences of infection are more severe in settings with limited access to oral rehydration therapy and emergency medical care. Travelers with young children to rural areas of sub-Saharan Africa, South Asia, and parts of South-East Asia should be prepared to manage acute gastroenteritis, including carrying ORS packets, knowing how to prepare ORS, and understanding the signs of dehydration.
Travel health kit essentials for families with young children:
Oral rehydration salt (ORS) packets (carry at least 6–10 per child)
Clean water for ORS preparation (or water purification method)
Zinc supplements (if traveling to areas where they may not be available)
Digital thermometer
Written instructions for ORS preparation and dehydration assessment
Adults and rotavirus: Adult travelers are at low risk for severe rotavirus disease due to accumulated immunity from childhood infections. However, mild rotavirus gastroenteritis can occur and may contribute to "traveler's diarrhea" episodes. Standard food and water hygiene practices, while more effective against bacterial causes, are generally advisable.
Cruise ship and resort outbreaks: Rotavirus outbreaks are reported in enclosed travel settings including cruise ships and all-inclusive resorts, particularly during winter months. Rigorous hand hygiene is the primary prevention measure in these settings.
Statistics and geographic data
Rotavirus is the leading cause of severe diarrhea in children under 5 years worldwide and one of the most common childhood infections globally. Its epidemiology has been dramatically altered by the introduction of rotavirus vaccines, creating a clear pre-vaccine and post-vaccine epidemiological landscape.
Pre-vaccine global burden (circa 2000): An estimated 527,000 deaths in children under 5 annually, representing approximately 37% of all diarrhea-attributable deaths in this age group. Approximately 2.4 million hospitalizations and 25 million clinic visits annually. Over 95% of deaths occurred in low-income countries in sub-Saharan Africa and South Asia. In high-income countries, rotavirus caused significant morbidity (hospitalizations, emergency visits) but relatively few deaths.
Post-vaccine global burden (circa 2016–2020): Following vaccine introduction in 120+ countries, rotavirus mortality has declined to approximately 128,500 deaths annually (>60% reduction from pre-vaccine era). In countries with early and high vaccine coverage, the impact has been transformative: the United States has seen a 60–90% reduction in rotavirus hospitalizations, and similar reductions have been documented in Australia, Europe, Brazil, Mexico, and South Africa.
Genotype distribution and dynamics: Six genotypes (G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], G12P[8]) collectively account for approximately 90% of infections globally, though relative prevalence varies by region and year. Post-vaccine surveillance has detected genotype shifts (e.g., relative increase in G2P[4] in some settings using the monovalent G1P[8] vaccine), though both RotaTeq and Rotarix maintain effectiveness against heterologous strains.
Seasonality: Rotavirus exhibits marked winter seasonality in temperate climates, with distinct peaks from December to May in the Northern Hemisphere. In tropical regions, transmission is year-round with variable peaks. Post-vaccine, the seasonal pattern has been disrupted in many countries, with reduced peak height and biennial oscillation patterns observed.
Age distribution: Median age of severe rotavirus disease is 9–12 months in low-income countries and 12–18 months in high-income countries. This age difference reflects earlier and more intense exposure in low-income settings. Vaccine introduction has shifted the age distribution of disease toward older, unvaccinated cohorts.
Who is most at risk
Risk factors for rotavirus gastroenteritis and its severe outcomes reflect the interplay between host susceptibility, exposure intensity, and access to care.
Risk factors for infection:
Age 6–24 months: The highest-risk period, as maternal antibody protection wanes while natural immunity has not yet developed through repeated exposures
Lack of rotavirus vaccination: Unvaccinated children have a near-100% lifetime risk of infection, with first infections typically being the most severe
Childcare/daycare attendance: Rotavirus spreads efficiently in childcare settings; attack rates can reach 50–70% during outbreaks
Household crowding: Close contact with infected siblings or family members. Secondary household attack rates are 30–50%
Seasonality: Winter months in temperate climates (December–April in the Northern Hemisphere); year-round with variable peaks in tropical regions
Lack of breastfeeding: Non-breastfed infants have approximately twice the risk of hospitalization compared to exclusively breastfed infants
Risk factors for severe disease and complications:
Young age: Severity peaks at 6–24 months. Neonates (especially premature) may develop necrotizing enterocolitis in severe cases
Malnutrition: Malnourished children experience more severe and prolonged disease, and rotavirus in turn exacerbates malnutrition, creating a vicious cycle
Immunodeficiency: Children with severe combined immunodeficiency (SCID), HIV/AIDS, or organ transplant recipients may develop chronic, prolonged rotavirus infection lasting weeks to months with continuous viral shedding
Limited healthcare access: The single most important determinant of rotavirus mortality is access to timely rehydration therapy. Distance from health facilities, cost barriers, and lack of caregiver knowledge about ORS use are major risk factors for death
Co-infection: Concurrent infections with other enteric pathogens may worsen disease severity and complicate management
Protective factors that reduce severity:
Rotavirus vaccination (most important modifiable factor)
Exclusive breastfeeding for the first 6 months
Adequate nutritional status
Access to clean water for ORS preparation
Prior rotavirus infection (natural immunity)
Potential complications
While rotavirus gastroenteritis is self-limiting in most cases, complications can be severe and life-threatening, particularly in young children in resource-limited settings.
Dehydration is the primary complication and cause of mortality. Rotavirus causes both osmotic diarrhea (due to malabsorption from villous destruction and accumulation of undigested disaccharides) and secretory diarrhea (mediated by the NSP4 enterotoxin, which triggers chloride secretion). Combined with vomiting and fever-related insensible losses, children can lose 5–15% of body weight in fluid within 24–48 hours. Severe dehydration leads to hypovolemic shock, metabolic acidosis, electrolyte derangements (hypernatremic or hyponatremic dehydration, hypokalemia), acute kidney injury, and death if untreated. Hypernatremic dehydration is particularly common and carries risk of cerebral venous thrombosis and seizures during correction.
Seizures occur in approximately 2–7% of hospitalized children with rotavirus gastroenteritis, and may be febrile or afebrile. Benign afebrile seizures associated with rotavirus (sometimes called "rotavirus seizures") are self-limiting and do not increase the risk of epilepsy, but must be distinguished from seizures secondary to severe electrolyte abnormalities or CNS infection.
Intussusception has been epidemiologically associated with rotavirus infection (independent of vaccination), with an estimated 1.5–2-fold increased risk during the first week of symptomatic infection. Intussusception presents with intermittent colicky abdominal pain, "currant jelly" stool, and a palpable abdominal mass, requiring urgent radiological reduction (pneumatic or hydrostatic) or surgical intervention.
Necrotizing enterocolitis (NEC) may occur in premature neonates with rotavirus infection, representing a severe and potentially fatal complication with mortality rates of 20–30% in affected neonates.
Secondary lactose intolerance affects a significant proportion of children following rotavirus infection, due to destruction of lactase-producing enterocytes at the villous tips. This transient condition may persist for 2–6 weeks after acute illness, causing bloating, watery stools, and abdominal discomfort with dairy consumption. It resolves spontaneously as the intestinal epithelium regenerates.
Nutritional complications are particularly important in low-income settings. Each episode of rotavirus diarrhea results in an average weight loss of 200–300 grams in young children, and repeated episodes contribute to growth faltering, stunting, and micronutrient deficiencies.
Expected outcomes and recovery
The prognosis of rotavirus gastroenteritis is excellent with appropriate rehydration therapy but remains a significant cause of death when treatment access is limited.
In high-income countries, rotavirus mortality is rare — approximately 20–70 deaths per year in the United States (pre-vaccine era). Hospitalization rates were approximately 55,000–70,000 annually in children under 5 in the US pre-vaccine, with a case fatality rate among hospitalized children of less than 0.01%. With vaccine introduction, hospitalizations have declined by 60–90%.
In low- and middle-income countries, the prognosis is significantly impacted by access to healthcare and rehydration. Pre-vaccine mortality was estimated at 527,000 deaths annually in children under 5 (2000 estimate), primarily in sub-Saharan Africa and South Asia. Post-vaccine, mortality has declined to approximately 128,500 deaths annually (2016), but this remains substantial. The case fatality rate in resource-limited settings can reach 0.5–1% of symptomatic infections.
Age-specific prognosis: Disease severity follows an inverted U-shaped curve with age. Neonates are relatively protected by maternal antibodies, peak severity occurs at 6–24 months, and subsequent infections are progressively milder. By adulthood, most individuals have substantial immunity, and rotavirus infection typically causes only mild or asymptomatic illness. Immunocompromised patients (organ transplant recipients, HIV-positive children with low CD4 counts, children with severe combined immunodeficiency) may experience prolonged, severe, and potentially chronic rotavirus diarrhea.
Nutritional impact: Even in non-fatal cases, repeated rotavirus episodes contribute to the cycle of malnutrition and diarrhea in low-income settings. Illness-associated malabsorption, reduced caloric intake, and catabolic losses can impair growth. Children who experience multiple diarrheal episodes in the first 2 years of life are at risk for stunting, cognitive impairment, and reduced school performance.
Long-term immunity: Natural infection provides progressively increasing protection against subsequent infections. After a first infection, protection against subsequent severe rotavirus gastroenteritis is approximately 77%, increasing to 87% after two infections.
This disease is vaccine-preventable. Effective protection is available through vaccination.
Talk to a travel health specialist about the recommended schedule before your trip.
Find a vaccination clinic →The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.
Full terms of useKnow which vaccine you need? Great. Not sure? Just tell us your destination — we will figure it out and match you with a clinic. Free, no obligation.